Christof Vulsteke, MD, PhD, discusses the clinical rationale for evaluating perioperative enfortumab vedotinplus pembrolizumab in patients with cisplatin-ineligible MIBC.
Christof Vulsteke, MD, PhD
Advertisement
Christof Vulsteke, MD, PhD, is head of the Integrated Cancer Center Ghent
Articles by Christof Vulsteke, MD, PhD
Christof Vulsteke, MD, PhD, discusses the significance of the FDA approval of enfortumab vedotin plus pembrolizumab for cisplatin-ineligible MIBC.
Dr Vulsteke discusses the FDA approval of enfortumab vedotin plus pembrolizumab for patients with cisplatin-ineligible muscle-invasive bladder cancer.
Advertisement
Latest Updated Articles
Dr Vulsteke on the FDA Approval of Enfortumab Vedotin Plus Pembrolizumab for Cisplatin-Ineligible MIBCPublished: January 7th 2026 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
The Role of Elacestrant in ER+/HER2– Advanced Breast Cancer Harboring ESR1 Mutations
2
Nemtabrutinib With Venetoclax Shows Promising Activity in R/R CLL/SLL
3
Pembrolizumab Fails to Yield Responses in Recurrent Medullary Thyroid Cancer
4
Dr Raghav on the Rationale for Investigating Telisotuzumab Adizutecan in ctDNA+ CRC
5